The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Abstract
Purpose: To describe survival in previously treated patients with metastatic renal cell carcinoma (RCC) who are candidates for clinical trials of new agents as second-line therapy. Patients and Methods: The relationship between pretreatment clinical features and survival was studied in 251 patients with advanced RCC treated during 29 consecutive clinical trials between 1975 and 2002. Clinical features were first examined in univariate analyses, and then a stepwise modeling approach based on Cox regression was used to form a multivariate model. Results: Median survival for the 251 patients was 10.2 months and differed according to year of treatment, with patients treated after 1990 showing longer survival. In this group, the median overall survival time was 12.7 months. Because the purpose of this analysis was to establish prognostic factors for present-day clinical trial design, prognostic factor analysis was performed on these patients. Pretreatment features associated with a shorter survival in the multivariate analysis were low Karnofsky performance status, low hemoglobin level, and high corrected serum calcium. These were used as risk factors to categorize patients into three different groups. The median time to death in patients with zero risk factors was 22 months. The median survival in patients with one of these prognostic factors was 11.9 months. Patients with two or three risk factors had a median survival of 5.4 months. Conclusion: Treatment with novel agents during a clinical trial is indicated for patients with metastatic RCC after progression to cytokine treatment. Three prognostic factors for predicting survival were used to categorize patients into risk groups. These risk categories can be used in clinical trial design and interpretation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Motzer, R. J., Bander, N. H., & Nanus, D. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351207 · Cited by 2,219
Self-citationSurvival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Self-citationMotzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
Self-citationChilds, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., Read, E. J., Tisdale, J., Dunbar, C., Linehan, W. M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009143431101 · Cited by 998
SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
MOTZER, R. J., & RUSSO, P. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67889-5 · Cited by 603
Self-citation(1999) · The Lancet · doi:10.1016/s0140-6736(98)03544-2 · Cited by 601
Cited by
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Self-citationSorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
Ljungberg, B., Bensalah, K., Canfield, S., Dabestani, S., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T., Marconi, L., Merseburger, A. S., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.005 · Cited by 3,394
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Self-citationRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., Eisen, T., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu259 · Cited by 2,251
Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study
Hurria, A., Togawa, K., Mohile, S. G., Owusu, C., Klepin, H. D., Gross, C. P., Lichtman, S. M., Gajra, A., Bhatia, S., Katheria, V., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7625 · Cited by 1,841
Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, M. D., Gorbunova, V. A., Gore, M. E., Rusakov, I. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,840
Self-citationDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Self-citationCohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,554
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Choueiri, T. K., Escudier, B., Powles, T., Mainwaring, P. N., Rini, B. I., Donskov, F., Hammers, H., Hutson, T. E., Lee, J.-L., Peltola, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510016 · Cited by 1,239
Self-citationSunitinib in Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., Redman, B. G., Margolin, K. A., Merchan, J. R., Wilding, G., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2516 · Cited by 1,230
Self-citationMotzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2010) · Cancer · doi:10.1002/cncr.25219 · Cited by 1,139
Self-citationNivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0703 · Cited by 1,074
Self-citationBraun, D. A., Hou, Y., Bakouny, Z., Ficial, M., Sant’ Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A. C., Jegede, O. A., Elagina, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0839-y · Cited by 992
Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M., Desai, A. A., Patnaik, A., Xiong, H. Q., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6723 · Cited by 1,032
Choueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F., Roth, B. J., Peltola, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 958
Self-citationMotzer, R. J., Escudier, B., Tomczak, P., Hutson, T. E., Michaelson, M. D., Negrier, S., Oudard, S., Gore, M. E., Tarazi, J., Hariharan, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70093-7 · Cited by 745
Self-citationValidation of a prediction tool for chemotherapy toxicity in older adults with cancer
Hurria, A., Mohile, S., Gajra, A., Klepin, H., Muss, H., Chapman, A., Feng, T., Smith, D., Sun, C.-L., De Glas, N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.4327 · Cited by 598
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Gore, M. E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G. A., Oudard, S., Hariharan, S., Lee, S.-H., Haanen, J., Castellano, D., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70162-7 · Cited by 589
Goodman, V. L., Rock, E. P., Dagher, R., Ramchandani, R. P., Abraham, S., Gobburu, J. V. S., Booth, B. P., Verbois, S. L., Morse, D. E., Liang, C. Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2328 · Cited by 501
Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents
Lee, J. J., & Swain, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0543 · Cited by 472
Targeted Therapy for Metastatic Renal Cell Carcinoma
Motzer, R. J., & Bukowski, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5415 · Cited by 454
Self-citationRixe, O., Bukowski, R. M., Michaelson, M. D., Wilding, G., Hudes, G. R., Bolte, O., Motzer, R. J., Bycott, P., Liau, K. F., Freddo, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70285-1 · Cited by 435
Self-citationSurvival after complete surgical resection of multiple metastases from renal cell carcinoma
Alt, A. L., Boorjian, S. A., Lohse, C. M., Costello, B. A., Leibovich, B. C., & Blute, M. L. (2011) · Cancer · doi:10.1002/cncr.25836 · Cited by 426
Hutson, T. E., Lesovoy, V., Al-Shukri, S., Stus, V. P., Lipatov, O. N., Bair, A. H., Rosbrook, B., Chen, C., Kim, S., & Vogelzang, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70465-0 · Cited by 404
Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393
Rini, B. I., Michaelson, M. D., Rosenberg, J. E., Bukowski, R. M., Sosman, J. A., Stadler, W. M., Hutson, T. E., Margolin, K., Harmon, C. S., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5416 · Cited by 393
Ko, J. J., Xie, W., Kroeger, N., Lee, J.-L., Rini, B. I., Knox, J. J., Bjarnason, G. A., Srinivas, S., Pal, S. K., Yuasa, T., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71222-7 · Cited by 382
Tannir, N. M., Jonasch, E., Albiges, L., Altinmakas, E., Ng, C. S., Matin, S. F., Wang, X., Qiao, W., Dubauskas Lim, Z., Tamboli, P., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.10.049 · Cited by 364
Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
Sun, M., Shariat, S. F., Cheng, C., Ficarra, V., Murai, M., Oudard, S., Pantuck, A. J., Zigeuner, R., & Karakiewicz, P. I. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.041 · Cited by 325
Motzer, R. J., Porta, C., Vogelzang, N. J., Sternberg, C. N., Szczylik, C., Zolnierek, J., Kollmannsberger, C., Rha, S. Y., Bjarnason, G. A., Melichar, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70030-0 · Cited by 262
Self-citationEscudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.02.010 · Cited by 256
Self-citationMetabolomic adaptations and correlates of survival to immune checkpoint blockade
Li, H., Bullock, K., Gurjao, C., Braun, D., Shukla, S. A., Bossé, D., Lalani, A.-K. A., Gopal, S., Jin, C., Horak, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12361-9 · Cited by 218
Rossi, J.-F., Négrier, S., James, N. D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P., & Berns, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605872 · Cited by 166
Metadata
- Authors
- Motzer, R. J., Bacik, J., Schwartz, L. H., Reuter, V., Russo, P., Marion, S., & Mazumdar, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-02-01
- Volume
- 22
- Issue
- 3
- Pages
- 454-463
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106453307
- Cited by
- 793
- References
- 28
- FWCI
- 33.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.